The Conversation (0)
Cardiome Pharma kicked off the commercial launch of Xydalba, their treatment of acute bacterial skin and skin structure infections in adults, in Sweden, Finland and the Republic of Ireland.
Cardiome Pharma (NASDAQ:CRME; TSX:COM) kicked off the commercial launch of Xydalba, their treatment of acute bacterial skin and skin structure infections in adults, in Sweden, Finland and the Republic of Ireland.
As quoted in the press release:
“We’re making steady progress in advancing the commercial availability of Xydalba throughout our licensed territories and have now launched this important antibiotic in a total of six European countries,” said Hugues Sachot, Cardiome’s Chief Commercial Officer. “Our established commercial infrastructure throughout Europe continues to support these launches and ensures that patients suffering from infectious disease have access to this acute care treatment.”
“Xydalba offers medical professionals a flexible dosing option that will allow them to best manage therapy of this serious infection based on individual patient need,” said Dr. William Hunter, Cardiome’s President and CEO. “Our geographic footprint continues to expand, allowing us to make our portfolio of differentiated hospital products available to patients through our ex-U.S. global distribution capabilities and as we build a world-class acute care pharmaceutical company.
Click here to read the full press release.
Source: www.newswire.ca
